Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
Conditions
Interventions
Zanubrutinib
Rituximab
+1 more
Locations
3
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Start Date
January 21, 2025
Primary Completion Date
March 1, 2028
Completion Date
March 1, 2030
Last Updated
February 19, 2026
NCT07249528
NCT04570423
NCT00131014
NCT03050268
NCT07545603
NCT07137494
Lead Sponsor
Reid Merryman, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions